InnoCare Pharma Ltd. (688428.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 28.82

From 52W high−13.72%

Volume9.55M

Market capCNY 48.72B

P/E (TTM)75.8x

P/S (TTM)19.9x

Div yield—

Key dataSep 18, 2026

Open

CNY 28.82

From 52W high

−13.72%

Volume

9.55M

Market cap

CNY 48.72B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

61.0x

P/E (TTM)

75.8x

RSI (14)

47.3

MomentumView details →

1D Return

−6.96%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

75.8x

EV/EBITDA

61.0x

EV/Sales

18.0x

P/S (TTM)

19.9x

P/B (TTM)

6.6x

ProfitabilityView details →

Gross Margin

91.37%

Net Margin

28.95%

EBITDA Margin

29.50%

ROE (TTM)

9.94%

ROA (TTM)

7.03%

Asset Turnover

0.24x

GrowthView details →

Revenue YoY

+105.92%

EPS YoY

—

FCF YoY

+85.10%

Revenue CAGR 3Y

+56.01%

EPS CAGR 3Y

+246.15%

EBITDA YoY

—

MomentumView details →

1D Return

−6.96%

YTD Return

—

1Y Return

—

RSI (14)

47.3

vs 50D SMA

−1.84%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

5.65x

Quick Ratio

5.53x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.78B

Net Income (TTM)

918.32M

Op. CF (TTM)

247.17M

Latest newsMore news →

Innolux Corporation is restructuring its factories, with its second plant scheduled to close in September 2026, prompting subsidiary InnoCare Optoelectronics to prepare for a major supply-chain adjustment.9d ago

Innocare Pharma announced that its self-developed bispecific antibody-drug conjugate ICP-B381 targeting PSMA and STEAP1 received clinical trial approval from China's NMPA CDE for treating solid tumors including prostate cancer, marking the company's first bispecific ADC and third ADC candidate to enter clinical development.12d ago

Latest newsMore news →

Innolux Corporation is restructuring its factories, with its second plant scheduled to close in September 2026, prompting subsidiary InnoCare Optoelectronics to prepare for a major supply-chain adjustment.9d ago Innocare Pharma announced that its self-developed bispecific antibody-drug conjugate ICP-B381 targeting PSMA and STEAP1 received clinical trial approval from China's NMPA CDE for treating solid tumors including prostate cancer, marking the company's first bispecific ADC and third ADC candidate to enter clinical development.12d ago